$ENTX News

Entera Bio Announces Presentations Of New Data Supporting Its Oral Peptide Pipeline At The Annual Endochrine Society Meeting On June 13-16

HC Wainwright & Co. Maintains Buy on Entera Bio, Lowers Price Target to $9

Entera Bio Ltd. (ENTX) Discusses Osteoporosis Treatment Landscape and Clinical Potential of EB613 Oral Tablet Transcript

Entera Bio Raises $10M In Private Placement Led by BVF Partners, With Potential To Reach $24.5M

Entera Bio Q4 EPS $(0.06) Beats $(0.09) Estimate

Entera Bio Submits Clinical Amendment To FDA Providing Streamlined Phase 3 Protocol, SAP, And Open-Label Extension Synopsis To IND 505(B)(2) Submission To Evaluate EB613; Entera Expects FDA Feedback Within 60 Days

What Pushed Entera Bio (ENTX) To Rally Nearly 16% After Hours

Entera Bio shares are trading higher after the company announced that several members of its Board of Directors have made open market purchases of its ordinary shares.

Entera Bio shares are trading higher after the company announced that several members of its Board of Directors have made open market purchases of its ordinary shares.

Entera Bio shares are trading higher after the company announced the appointment of Geno Germano as Chairman of the Board.

Entera Bio Appoints Geno Germano As Chairman Of The Board, Succeeding Gerald Lieberman

Entera Bio Congratulates the FNIH-ASBMR-SABRE Team on FDA’s Qualification of Total Hip BMD as Regulatory Endpoint: Huge Win for Osteoporosis Innovation

Entera Bio Announces New Data Supporting Further Development of a Proprietary First-in-Class Oral, Long-Acting PTH Tablet for Patients with Hypoparathyroidism (EB612 Program)

Entera Bio Announces New Validating In Vivo Pharmacokinetic And Pharmacodynamic Data That Supports Development Of Proprietary Long-Acting PTH Analog Using N-Tab Platform For Patients With Hypoparathyroidism

Entera Bio to Participate in the 8th Annual Evercore ISI Healthcare Conference

Entera Bio Q3 EPS $(0.07) Beats $(0.09) Estimate

Entera Bio Presents Positive New Clinical Data from EB613 Phase 2 Trial Demonstrating Significant Bone Density Improvements in Early Postmenopausal Women

Entera Bio Presents New Clinical Data From Phase 2 Study Of EB613 At 2025 North American Menopause Society Annual Meeting; Intends To Initiate Global Registrational Phase 3 Trial After July 2025 FDA Concurrence

Entera Bio Releases New Phase 2 Data At NAMS 2025 Showing That EB613, An Oral PTH[1-34] Therapy, Consistently Increased Bone Mineral Density In Both Early Postmenopausal Women And Those 10 Years Post-Menopause

Entera Bio Announces It Will Present New Phase 2 Clinical Data For EB613 At The North American Menopause Society 2025 Annual Meeting, October 21–25, 2025, In Orlando, Florida.